Harker W G, Bauer D, Etiz B B, Newman R A, Sikic B I
Cancer Res. 1986 May;46(5):2369-73.
The effects of verapamil on the cytotoxicity and accumulation of multiple drugs were studied in a model of pleiotropic resistance generated by doxorubicin (DOX) selection of the human sarcoma cell line MES-SA. The in vitro sensitivity of the DOX-resistant variant (named Dx5), which is 50- to 100-fold resistant to DOX compared to MES-SA, was enhanced approximately 7-fold by verapamil (3 micrograms/ml). In addition, the cytotoxicity of several agents to which the Dx5 line displays cross-resistance, i.e., daunorubicin, dactinomycin, mitoxantrone, and etoposide, was also enhanced 2- to 14-fold by verapamil. These agents share the properties of DNA intercalation and/or interaction with topoisomerase II. In contrast, verapamil did not alter the sensitivity of Dx5 to several other agents to which cross-resistance had been demonstrated, i.e., vincristine, vinblastine, colchicine, mitomycin C, and melphalan; nor did verapamil enhance the cytotoxicity of DOX or other agents against the DOX-sensitive parent, MES-SA. The sensitizing effect of verapamil did not correlate well with its effects on intracellular drug accumulation. [14C]DPX accumulation was increased by 30-40% in Dx5 but not in MES-SA cells in the presence of verapamil. [3H]Vinblastine accumulation was increased by 24-72% in both MES-SA and Dx5 cells in the presence of verapamil, although cytotoxicity of the Vinca alkaloids was not affected. In this human sarcoma model of DOX-selected pleiotropic resistance, verapamil partially reversed the resistance to DOX, as well as four of the nine drugs for which cross-resistance had been demonstrated in Dx5. The potentiation by verapamil of the cytotoxicity of some but not all of these antitumor agents suggests that factors other than altered drug transport may be responsible. The pattern of sensitization, restricted to agents which produce DNA strand scission by interaction with topoisomerase II, suggests that verapamil may be acting to promote the formation or inhibit the repair of such DNA strand breaks.
在通过阿霉素(DOX)筛选人肉瘤细胞系MES-SA产生的多药耐药模型中,研究了维拉帕米对多种药物细胞毒性和蓄积的影响。与MES-SA相比,对DOX耐药50至100倍的DOX耐药变体(命名为Dx5)的体外敏感性,在维拉帕米(3微克/毫升)作用下提高了约7倍。此外,Dx5细胞系对其显示交叉耐药的几种药物,即柔红霉素、放线菌素D、米托蒽醌和依托泊苷的细胞毒性,也因维拉帕米而提高了2至14倍。这些药物具有DNA嵌入和/或与拓扑异构酶II相互作用的特性。相比之下,维拉帕米并未改变Dx5对已证明存在交叉耐药的其他几种药物的敏感性,即长春新碱、长春碱、秋水仙碱、丝裂霉素C和美法仑;维拉帕米也未增强DOX或其他药物对DOX敏感亲本MES-SA的细胞毒性。维拉帕米的致敏作用与其对细胞内药物蓄积的影响相关性不佳。在维拉帕米存在的情况下,[14C]DPX在Dx5细胞中的蓄积增加了30%至40%,但在MES-SA细胞中未增加。在维拉帕米存在的情况下,[3H]长春碱在MES-SA和Dx5细胞中的蓄积均增加了24%至72%,尽管长春花生物碱的细胞毒性未受影响。在这个DOX诱导的多药耐药人肉瘤模型中,维拉帕米部分逆转了对DOX的耐药性,以及Dx5中已证明存在交叉耐药的九种药物中的四种。维拉帕米对某些但并非所有这些抗肿瘤药物细胞毒性的增强作用表明,可能还有其他因素而非药物转运改变起作用。致敏模式仅限于通过与拓扑异构酶II相互作用产生DNA链断裂的药物,这表明维拉帕米可能是通过促进此类DNA链断裂的形成或抑制其修复而起作用。